Metformin Oresund Pharma

Metformin, the active ingredient in Metformin Oresund Pharma, is a Biguanide presented as an oral tablet for oral use. It lowers blood glucose levels by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, and is used to treat type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformin Oresund Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for global healthcare providers through established distribution networks.

Metformin is indicated for conditions within the type 2 diabetes mellitus pathway.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Prediabetes: may delay progression to overt diabetes when combined with lifestyle modification. - Polycystic ovary syndrome (PCOS): helps improve insulin resistance and may normalize menstrual cycles.

Metformin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycaemia: usually when combined with insulin or sulfonylureas. - Hepatotoxicity: uncommon liver enzyme elevation. - Skin reactions: rash or Stevens‑Johnson syndrome in rare cases.

When prescribing Metformin, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic impairment: avoid or use with caution in patients with significant liver disease. - Cardiovascular status: monitor for signs of heart failure, especially in high‑risk patients. - Concomitant medications: review for drugs that may increase risk of lactic acidosis. - Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Metformin interacts with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise Metformin plasma concentrations, heightening toxicity. - Nucleoside reverse transcriptase inhibitors (e.g., didanosine): increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Diuretics: can reduce renal clearance of Metformin. - Beta‑blockers: may mask hypoglycaemia symptoms. - Alcohol: excessive intake can potentiate lactic acidosis.